We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · September 13, 2022

Predictive Genomic Biomarkers for Response to Cisplatin-Based Neoadjuvant Chemotherapy in MIBC

European Urology


Additional Info

European Urology
Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer
Eur Urol 2022 Aug 11;[EPub Ahead of Print], A Gil-Jimenez, J van Dorp, A Contreras-Sanz, K van der Vos, DJ Vis, L Braaf, A Broeks, R Kerkhoven, KEM van Kessel, MJ Ribal, A Alcaraz, LFA Wessels, R Seiler, JL Wright, L Mengual, J Boormans, BWG van Rhijn, PC Black, MS van der Heijden

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading